Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short all-oral regimen for rifampicin-resistant tuberculosis in Niger
PACTR202203645724919Phase 3Recruiting
- Sponsor
- Damien Foundation
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 3 trial in Tuberculosis (TB) (2 arms), sponsored by Damien Foundation. Primary endpoint: Any grade 3-5 adverse event. Started Apr 2021; status: recruiting.
02
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202203645724919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203645724919.